Enveric Biosciences Announces 2024 Annual Meeting of Stockholders
Ticker: ENVB · Form: DEF 14A · Filed: Apr 16, 2024 · CIK: 890821
| Field | Detail |
|---|---|
| Company | Enveric Biosciences, Inc. (ENVB) |
| Form Type | DEF 14A |
| Filed Date | Apr 16, 2024 |
| Risk Level | |
| Pages | 16 |
| Reading Time | 19 min |
| Key Dollar Amounts | $0.01, $10,100 |
| Sentiment | neutral |
Sentiment: neutral
Topics: Enveric Biosciences, Annual Meeting, Proxy Statement, Executive Compensation, Auditor Ratification
TL;DR
<b>Enveric Biosciences will hold its 2024 Annual Meeting of Stockholders virtually on May 28, 2024, to elect directors, approve executive compensation, and ratify auditor appointment.</b>
AI Summary
Enveric Biosciences, Inc. (ENVB) filed a Proxy Statement (DEF 14A) with the SEC on April 16, 2024. The 2024 Annual Meeting of Stockholders for Enveric Biosciences, Inc. will be held on May 28, 2024, at 10:00 a.m. Eastern Time. The meeting will be conducted exclusively via live webcast at www.virtualshareholdermeeting.com/ENVB2024. Six individuals will be elected to the Board of Directors. Stockholders will vote on a non-binding advisory basis to approve the compensation of named executive officers. The appointment of Marcum LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, will be ratified.
Why It Matters
For investors and stakeholders tracking Enveric Biosciences, Inc., this filing contains several important signals. This proxy statement outlines the agenda for the annual meeting, including director elections and executive compensation, which are key governance matters for stockholders. The virtual format of the meeting aims to increase accessibility for stockholders to participate in important company decisions.
Risk Assessment
Risk Level: — Enveric Biosciences, Inc. shows moderate risk based on this filing. The filing is a routine proxy statement for an annual meeting and does not contain new financial or operational information that would indicate significant risk.
Analyst Insight
Stockholders should review the proxy materials to understand the proposals and vote on director elections and executive compensation.
Key Numbers
- 6 — Directors to be elected (Number of individuals to be elected to the Board of Directors at the Annual Meeting.)
- 2024 — Annual Meeting Year (The year of the Annual Meeting of Stockholders.)
- 2024 — Fiscal Year End (The company's fiscal year end date.)
Key Players & Entities
- Enveric Biosciences, Inc. (company) — Registrant and filer of the proxy statement.
- May 28, 2024 (date) — Date of the 2024 Annual Meeting of Stockholders.
- Marcum LLP (company) — Proposed independent registered public accounting firm.
- 2024 (date) — Fiscal year for which Marcum LLP is proposed as auditor.
FAQ
When did Enveric Biosciences, Inc. file this DEF 14A?
Enveric Biosciences, Inc. filed this Proxy Statement (DEF 14A) with the SEC on April 16, 2024.
What is a DEF 14A filing?
A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by Enveric Biosciences, Inc. (ENVB).
Where can I read the original DEF 14A filing from Enveric Biosciences, Inc.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Enveric Biosciences, Inc..
What are the key takeaways from Enveric Biosciences, Inc.'s DEF 14A?
Enveric Biosciences, Inc. filed this DEF 14A on April 16, 2024. Key takeaways: The 2024 Annual Meeting of Stockholders for Enveric Biosciences, Inc. will be held on May 28, 2024, at 10:00 a.m. Eastern Time.. The meeting will be conducted exclusively via live webcast at www.virtualshareholdermeeting.com/ENVB2024.. Six individuals will be elected to the Board of Directors..
Is Enveric Biosciences, Inc. a risky investment based on this filing?
Based on this DEF 14A, Enveric Biosciences, Inc. presents a moderate-risk profile. The filing is a routine proxy statement for an annual meeting and does not contain new financial or operational information that would indicate significant risk.
What should investors do after reading Enveric Biosciences, Inc.'s DEF 14A?
Stockholders should review the proxy materials to understand the proposals and vote on director elections and executive compensation. The overall sentiment from this filing is neutral.
How does Enveric Biosciences, Inc. compare to its industry peers?
Enveric Biosciences operates in the pharmaceutical preparations industry, focusing on drug development.
Are there regulatory concerns for Enveric Biosciences, Inc.?
The filing is made pursuant to Section 14(a) of the Securities Exchange Act of 1934, which governs the solicitation of proxies.
Risk Factors
- Director Elections [low — regulatory]: Six individuals will be elected to the Board of Directors, a standard governance procedure.
- Executive Compensation Approval [low — regulatory]: Stockholders will vote on a non-binding advisory basis to approve the compensation of named executive officers.
- Auditor Ratification [low — regulatory]: The appointment of Marcum LLP as the independent registered public accounting firm for fiscal year 2024 will be ratified.
Industry Context
Enveric Biosciences operates in the pharmaceutical preparations industry, focusing on drug development.
Regulatory Implications
The filing is made pursuant to Section 14(a) of the Securities Exchange Act of 1934, which governs the solicitation of proxies.
What Investors Should Do
- Review the proxy statement for details on director nominees and their qualifications.
- Understand the proposals related to executive compensation and vote accordingly.
- Confirm the ratification of Marcum LLP as the independent auditor for fiscal year 2024.
Key Dates
- 2024-05-28: 2024 Annual Meeting of Stockholders — Key date for stockholders to vote on company matters.
- 2024-04-16: Filing Date — Date the Definitive Proxy Statement was filed with the SEC.
Year-Over-Year Comparison
This is a DEF 14A filing for the 2024 Annual Meeting, indicating a routine annual governance event.
Filing Stats: 4,684 words · 19 min read · ~16 pages · Grade level 12.4 · Accepted 2024-04-16 08:30:15
Key Financial Figures
- $0.01 — holders of our common stock, par value $0.01 per share (“Common Stock”).
- $10,100 — he solicitation of proxies for a fee of $10,100 plus reimbursement of expenses. In addi
Filing Documents
- formdef14a.htm (DEF 14A) — 566KB
- formdef14a_001.jpg (GRAPHIC) — 133KB
- formdef14a_002.jpg (GRAPHIC) — 112KB
- proxy_001.jpg (GRAPHIC) — 243KB
- proxy_002.jpg (GRAPHIC) — 239KB
- 0001493152-24-014745.txt ( ) — 1568KB
Security Ownership of Certain Beneficial Owners and Management
Security Ownership of Certain Beneficial Owners and Management 27 Corporate Code of Conduct and Ethics 28 Other Matters 28 Stockholder Proposals and Nominations for Director 28 ENVERIC BIOSCIENCES, INC. 4851 Tamiami Trail N., Suite 200 Naples, FL 34103 PROXY 2024 ANNUAL MEETING OF STOCKHOLDERS To Be Held on May 28, 2024 Unless the context otherwise requires, references in this proxy statement to “we,” “us,” “our,” the “Company” or “Enveric” refer to Enveric Biosciences, Inc., a Delaware corporation and its consolidated subsidiaries as a whole. In addition, unless the context otherwise requires, references to “stockholders” are to the holders of our common stock, par value $0.01 per share (“Common Stock”). The accompanying proxy is solicited by the board of directors of the Company (the “Board”) on behalf of Enveric Biosciences, Inc. to be voted at the Company’s 2024 Annual Meeting of Stockholders (the “Annual Meeting”) to be held on Tuesday, May 28, 2024, and at any adjournment, continuation or postponement thereof, for the purposes set forth in the accompanying Notice of Internet Availability of Proxy Materials (the “Internet Availability Notice”). The Annual Meeting will be held virtually via a live webcast on the Internet on Tuesday, May 28, 2024, at 10:00 a.m., Eastern Time. If you held shares of our Common Stock at the close of business on April 1, 2024 (the “Record Date”), you are invited to attend the Annual Meeting virtually at www.virtualshareholdermeeting.com/ENVB2024 and if you held shares of our Common Stock at the close of business on the Record Date, you are invited to vote on the proposals described in this proxy statement. The Company will pay the costs of soliciting proxies from stockholders. We have retained Kingsdale Advisors to assist in the